Dovprela (pretomanid) receives positive CHMP opinion for on variation to marketing authorisation for treatment of TB – Viatris
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Dovprela. (pretomanid). The marketing… read more.

